Amgen Inc. $AMGN Shares Acquired by Hamilton Wealth LLC

Hamilton Wealth LLC raised its stake in Amgen Inc. (NASDAQ:AMGN) by 375.6% in the first quarter, HoldingsChannel reports. The fund owned 3,405 shares of the medical research company’s stock after purchasing an additional 2,689 shares during the period. Hamilton Wealth LLC’s holdings in Amgen were worth $1,198,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of AMGN. Robeco Institutional Asset Management B.V. lifted its stake in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after buying an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC purchased a new stake in Amgen during the 4th quarter worth approximately $1,669,000. Adell Harriman & Carpenter Inc. increased its stake in Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after buying an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Amgen during the fourth quarter valued at approximately $22,441,000. Finally, Robinhood Asset Management LLC acquired a new position in shares of Amgen during the fourth quarter valued at approximately $17,526,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $387.64 on Thursday. Amgen Inc. has a one year low of $269.77 and a one year high of $398.00. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a market cap of $209.21 billion, a PE ratio of 26.98, a P/E/G ratio of 3.98 and a beta of 0.41. The stock has a 50 day moving average price of $354.68 and a 200 day moving average price of $353.11.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.90 earnings per share. Equities research analysts expect that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s monthly weight-loss drug remains a potentially significant long-term catalyst, with six Phase 3 trials underway. Success could give the company an opportunity to compete with Eli Lilly and Novo Nordisk in the fast-growing obesity-treatment market. Watch Out, Eli Lilly and Novo Nordisk: Amgen’s Monthly Weight Loss Drug Has 6 Phase 3 Trials Running
• Neutral Sentiment: Amgen will report second-quarter 2026 results after the market close on August 4, followed by a conference call with management. The event is the next major catalyst for the stock, particularly for updates on earnings, guidance and the obesity-drug program. Amgen Announces Webcast of 2026 Second Quarter Financial Results
• Negative Sentiment: Analysts cited a weaker setup for Amgen’s second-quarter report, with earnings expected to decline and the company lacking the indicators typically associated with a likely earnings beat. This may be pressuring the shares ahead of the results. Earnings Preview: Amgen Q2 Earnings Expected to Decline
• Negative Sentiment: Barclays raised its Amgen price target to $360 from $350 but maintained an “equal weight” rating. Because the target remains below the stock’s recent trading level, the call signals limited near-term upside and valuation caution. Barclays Raises Amgen Price Target
• Negative Sentiment: Despite the obesity opportunity, analysis also questions whether Amgen’s candidate will be competitive enough to capture meaningful market share. That uncertainty increases the risk surrounding the company’s long-term growth strategy. Amgen Weight-Loss Drug Competition Analysis

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research note on Friday, June 12th. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Mizuho raised their price objective on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a report on Tuesday, June 16th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Finally, Truist Financial upped their target price on shares of Amgen from $327.00 to $340.00 and gave the stock a “hold” rating in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $357.00.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.